{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:23:27Z","timestamp":1793413407582,"version":"4.5.0"},"reference-count":333,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["102176\/B\/13\/Z"],"award-info":[{"award-number":["102176\/B\/13\/Z"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009253","name":"European Association for the Study of the Liver","doi-asserted-by":"publisher","award":["2020RG03"],"award-info":[{"award-number":["2020RG03"]}],"id":[{"id":"10.13039\/501100009253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.jhep.2022.07.008","type":"journal-article","created":{"date-parts":[[2022,7,19]],"date-time":"2022-07-19T21:57:39Z","timestamp":1658267859000},"page":"1161-1197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":71,"title":["Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper"],"prefix":"10.1016","volume":"77","author":[{"given":"Thomas","family":"Marjot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7495-258X","authenticated-orcid":false,"given":"Christiane S.","family":"Eberhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Boettler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8714-2439","authenticated-orcid":false,"given":"Luca S.","family":"Belli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9246-4264","authenticated-orcid":false,"given":"Marina","family":"Berenguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Buti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7747-4015","authenticated-orcid":false,"given":"Rajiv","family":"Jalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario U.","family":"Mondelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0862-403X","authenticated-orcid":false,"given":"Richard","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Shouval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0003-6241","authenticated-orcid":false,"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9141-8001","authenticated-orcid":false,"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2022.07.008_bib1","article-title":"Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper","volume":"2","author":"Boettler","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2022.07.008_bib2","article-title":"Impact of COVID-19 on the care of patients with liver disease: EASL-ESCMID position paper after 6 months of the pandemic","volume":"2","author":"Boettler","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2022.07.008_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2021.01.032","article-title":"EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients","author":"Cornberg","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib4","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-022-04411-y","article-title":"Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa","author":"Viana","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2022.07.008_bib5","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/S0140-6736(21)02758-6","article-title":"Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic","volume":"398","author":"Karim","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.07.008_bib6","doi-asserted-by":"crossref","DOI":"10.1126\/science.abn8347","article-title":"Rapid increase in Omicron infections in England during December 2021: REACT-1 study","author":"Elliott","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jhep.2022.07.008_bib7","article-title":"The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic","author":"Hoffmann","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2022.07.008_bib8","article-title":"Comparison of total and neutralizing SARS-CoV-2 spike antibodies against omicron and other variants in paired samples after two or three doses of mRNA vaccine","author":"Debes","year":"2022","journal-title":"MedRxiv"},{"key":"10.1016\/j.jhep.2022.07.008_bib9","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa2119658","article-title":"Population immunity and Covid-19 severity with Omicron variant in South Africa","volume":"386","author":"Madhi","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib10","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0140-6736(22)00017-4","article-title":"Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study","volume":"399","author":"Wolter","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.07.008_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(22)00154-2","article-title":"Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study","author":"Bager","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2022.07.008_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-022-04479-6","article-title":"SARS-CoV-2 Omicron variant replication in human bronchus and lung ex\u00a0vivo","author":"Hui","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2022.07.008_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-022-04462-1","article-title":"Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant","author":"Suzuki","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2022.07.008_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2022.112911","article-title":"SARS-CoV-2 reinfections: overview of efficacy and duration of natural and hybrid immunity","volume":"209","author":"Pilz","year":"2022","journal-title":"Environ Res"},{"key":"10.1016\/j.jhep.2022.07.008_bib15","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41575-021-00426-4","article-title":"COVID-19 and liver disease: mechanistic and clinical perspectives","volume":"18","author":"Marjot","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib16","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s42255-022-00552-6","article-title":"Molecular consequences of SARS-CoV-2 liver tropism","volume":"4","author":"Wanner","year":"2022","journal-title":"Nat Metab"},{"key":"10.1016\/j.jhep.2022.07.008_bib17","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/apt.15996","article-title":"Liver involvement is not associated with mortality: results from a large cohort of SARS-CoV-2-positive patients","volume":"52","author":"Ponziani","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.07.008_bib18","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1136\/gutjnl-2020-323800","article-title":"Liver function test abnormalities at hospital admission are associated with severe course of SARS-CoV-2 infection: a prospective cohort study","volume":"70","author":"Weber","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.07.008_bib19","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jhep.2020.12.012","article-title":"Association of liver abnormalities with in-hospital mortality in patients with COVID-19","volume":"74","author":"Ding","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib20","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s13238-020-00718-6","article-title":"Recapitulation of SARS-CoV-2 infection and cholangiocyte damage with human liver ductal organoids","volume":"11","author":"Zhao","year":"2020","journal-title":"Protein Cell"},{"key":"10.1016\/j.jhep.2022.07.008_bib21","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1111\/liv.14971","article-title":"Secondary sclerosing cholangitis as cause of persistent jaundice in patients with severe COVID-19","volume":"41","author":"B\u00fctikofer","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.07.008_bib22","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.14309\/ajg.0000000000001264","article-title":"Cholangiopathy after severe COVID-19: clinical features and prognostic implications","volume":"116","author":"Faruqui","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.07.008_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/hep.32582","article-title":"Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in patients with chronic liver disease","author":"Hartl","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.008_bib24","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/hep.26459","article-title":"Ketamine abuse, biliary tract disease, and secondary sclerosing cholangitis","volume":"58","author":"Turkish","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.008_bib25","first-page":"e52","article-title":"Cholestasis and biliary dilatation associated with chronic ketamine abuse: a case series","volume":"52","author":"Lo","year":"2011","journal-title":"Singapore Med J"},{"key":"10.1016\/j.jhep.2022.07.008_bib26","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jhep.2021.02.007","article-title":"Intravenous ketamine and progressive cholangiopathy in COVID-19 patients","volume":"74","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib27","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/hep.31650","article-title":"Ketamine-induced sclerosing cholangitis (KISC) in a critically ill patient with COVID-19","volume":"74","author":"Knooihuizen","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.008_bib28","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1111\/apt.14367","article-title":"Cholangiopathy in critically ill patients surviving beyond the intensive care period: a multicentre survey in liver units","volume":"46","author":"Laurent","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2022.07.008_bib29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/2047-783X-17-30","article-title":"Abdominal obesity and prolonged prone positioning increase risk of developing sclerosing cholangitis in critically ill patients with influenza A-associated ARDS","volume":"17","author":"Weig","year":"2012","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.jhep.2022.07.008_bib30","first-page":"977","article-title":"Secondary cholangitis of the critically ill","volume":"57","author":"Hentschel","year":"2019","journal-title":"Z\u00a0Gastroenterol"},{"key":"10.1016\/j.jhep.2022.07.008_bib31","doi-asserted-by":"crossref","DOI":"10.1172\/JCI154886","article-title":"The intersection of COVID-19 and autoimmunity","volume":"131","author":"Knight","year":"2021","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.jhep.2022.07.008_bib32","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/art.41285","article-title":"On the alert for cytokine storm: immunopathology in COVID-19","volume":"72","author":"Henderson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib33","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/BOR.0000000000000776","article-title":"COVID-19 and autoimmune diseases","volume":"33","author":"Liu","year":"2021","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib34","doi-asserted-by":"crossref","first-page":"5417","DOI":"10.1038\/s41467-021-25509-3","article-title":"New-onset IgG autoantibodies in hospitalized patients with COVID-19","volume":"12","author":"Chang","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2022.07.008_bib35","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1111\/liv.15044","article-title":"Autoimmune hepatitis triggered by COVID-19: a report of two cases","volume":"41","author":"Kaba\u00e7am","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.07.008_bib36","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/imj.15420","article-title":"Autoimmune hepatitis triggered by COVID-19","volume":"51","author":"Hong","year":"2021","journal-title":"Intern Med J"},{"key":"10.1016\/j.jhep.2022.07.008_bib37","first-page":"64","article-title":"Autoimmune hepatitis triggered by COVID-19","volume":"114","author":"Mont\u00f3n Rodr\u00edguez","year":"2022","journal-title":"Rev Esp Enferm Dig"},{"key":"10.1016\/j.jhep.2022.07.008_bib38","article-title":"Autoimmune hepatitis-primary biliary cholangitis overlap syndrome triggered by COVID-19","volume":"8","author":"Singh","year":"2021","journal-title":"Eur J Case Rep Intern Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib39","doi-asserted-by":"crossref","DOI":"10.23736\/S2724-5985.21.03115-6","article-title":"Severe autoimmune hepatitis following recovery from COVID-19 - a novel mode of liver injury triggered by SARS-COV-2?","author":"Folman","year":"2022","journal-title":"Minerva Gastroenterol (Torino)"},{"key":"10.1016\/j.jhep.2022.07.008_bib40","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/cei.13623","article-title":"Establishing the prevalence of common tissue-specific autoantibodies following severe acute respiratory syndrome coronavirus 2 infection","volume":"205","author":"Richter","year":"2021","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.jhep.2022.07.008_bib41","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1038\/s41590-020-00814-z","article-title":"Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19","volume":"21","author":"Woodruff","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.jhep.2022.07.008_bib42","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2022.07.008_bib43","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1001\/jama.2020.6775","article-title":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area","volume":"323","author":"Richardson","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2022.07.008_bib44","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1002\/hep.31649","article-title":"Cirrhosis and severe acute respiratory syndrome coronavirus 2 infection in US veterans: risk of infection, hospitalization, ventilation, and mortality","volume":"74","author":"Ioannou","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.008_bib45","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jhep.2020.09.024","article-title":"Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study","volume":"74","author":"Marjot","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib46","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cgh.2020.09.027","article-title":"Predictors of outcomes of COVID-19 in patients with chronic liver disease: US multi-center study","volume":"19","author":"Kim","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib47","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1007\/s12072-020-10072-8","article-title":"Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; the APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)","volume":"14","author":"Sarin","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2022.07.008_bib48","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.jhep.2020.06.001","article-title":"High rates of 30-day mortality in patients with cirrhosis and COVID-19","volume":"73","author":"Iavarone","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib49","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/gutjnl-2020-322118","article-title":"Comparison of mortality risk in patients with cirrhosis and COVID-19 compared with patients with cirrhosis alone and COVID-19 alone: multicentre matched cohort","volume":"70","author":"Bajaj","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.07.008_bib50","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1053\/j.gastro.2021.07.010","article-title":"Outcomes of SARS-CoV-2 infection in patients with chronic liver disease and cirrhosis: a national COVID cohort collaborative study","volume":"161","author":"Ge","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.07.008_bib51","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jhep.2021.04.052","article-title":"Prognosis of French COVID-19 patients with chronic liver disease: a national retrospective cohort study for 2020","volume":"75","author":"Mallet","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib52","doi-asserted-by":"crossref","first-page":"m3731","DOI":"10.1136\/bmj.m3731","article-title":"Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study","volume":"371","author":"Clift","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2022.07.008_bib53","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s12876-021-02017-8","article-title":"Risk of severe COVID-19 and mortality in patients with established chronic liver disease: a nationwide matched cohort study","volume":"21","author":"Simon","year":"2021","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.jhep.2022.07.008_bib54","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2021-000739","article-title":"Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies","volume":"8","author":"Middleton","year":"2021","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.jhep.2022.07.008_bib55","doi-asserted-by":"crossref","first-page":"n2244","DOI":"10.1136\/bmj.n2244","article-title":"Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study","volume":"374","author":"Hippisley-Cox","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2022.07.008_bib56","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1001\/jamainternmed.2021.4325","article-title":"Association of BNT162b2 mRNA and mRNA-1273 vaccines with COVID-19 infection and hospitalization among patients with cirrhosis","volume":"181","author":"John","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib57","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S2468-1253(20)30126-6","article-title":"Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis","volume":"5","author":"Mao","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib58","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1136\/gut.2004.062398","article-title":"Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2","volume":"54","author":"Paizis","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.07.008_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.aohep.2021.100350","article-title":"Comparison of different prognostic scores for patients with cirrhosis hospitalized with SARS-CoV-2 infection","volume":"25","author":"Mendizabal","year":"2021","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib60","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.34147","article-title":"Disparities in COVID-19 outcomes by race, ethnicity, and socioeconomic status: a systematic-review and meta-analysis","volume":"4","author":"Magesh","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhep.2022.07.008_bib61","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jhep.2011.12.014","article-title":"The impact of organ dysfunction in cirrhosis: survival at a cost?","volume":"56","author":"Shawcross","year":"2012","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib62","doi-asserted-by":"crossref","first-page":"159","DOI":"10.35946\/arcr.v37.2.01","article-title":"Alcohol\u2019s effect on host defense","volume":"37","author":"Szabo","year":"2015","journal-title":"Alcohol Res"},{"key":"10.1016\/j.jhep.2022.07.008_bib63","doi-asserted-by":"crossref","first-page":"185","DOI":"10.35946\/arcr.v37.2.04","article-title":"Impact of alcohol abuse on the adaptive immune system","volume":"37","author":"Pasala","year":"2015","journal-title":"Alcohol Res"},{"key":"10.1016\/j.jhep.2022.07.008_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-022344","article-title":"Alcohol and the risk of pneumonia: a systematic review and meta-analysis","volume":"8","author":"Simou","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.jhep.2022.07.008_bib65","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1530-0277.2006.00084.x","article-title":"Cytokines and alcohol","volume":"30","author":"Crews","year":"2006","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.jhep.2022.07.008_bib66","unstructured":"Wider impacts of COVID-19 on health monitoring tool. GOVUK n.d. https:\/\/www.gov.uk\/government\/statistics\/wider-impacts-of-covid-19-on-health-monitoring-tool (accessed March 8, 2022)."},{"key":"10.1016\/j.jhep.2022.07.008_bib67","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jhep.2020.03.044","article-title":"Non-alcoholic fatty liver diseases in patients with COVID-19: a retrospective study","volume":"73","author":"Ji","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib68","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1097\/MEG.0000000000001902","article-title":"Nonalcoholic fatty liver disease is associated with COVID-19 severity independently of metabolic syndrome: a retrospective case-control study","volume":"33","author":"Mahamid","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib69","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1111\/liv.14583","article-title":"Impact of chronic liver disease on outcomes of hospitalized patients with COVID-19: a multicentre United States experience","volume":"40","author":"Hashemi","year":"2020","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.07.008_bib70","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.dsx.2021.03.019","article-title":"Non-alcoholic fatty liver disease and clinical outcomes in patients with COVID-19: a comprehensive systematic review and meta-analysis","volume":"15","author":"Singh","year":"2021","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.jhep.2022.07.008_bib71","article-title":"Metabolic associated fatty liver disease is associated with an increased risk of severe COVID-19: a systematic review with meta-analysis","volume":"8","author":"Hegyi","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jhep.2022.07.008_bib72","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jhep.2020.09.027","article-title":"Obese patients with NASH have increased hepatic expression of SARS-CoV-2 critical entry points","volume":"74","author":"Fondevila","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib73","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.jhep.2020.12.007","article-title":"Increased expression of key SARS-CoV-2 entry points in multiple tissues in individuals with NAFLD","volume":"74","author":"Meijnikman","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib74","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.jhep.2020.09.006","article-title":"NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - the debate continues","volume":"74","author":"Mushtaq","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib75","article-title":"Independent predictors of mortality among patients with NAFLD hospitalized with COVID-19 infection","author":"Younossi","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2022.07.008_bib76","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jhep.2020.05.015","article-title":"Lack of genetic evidence that fatty liver disease predisposes to COVID-19","volume":"73","author":"Valenti","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib77","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1053\/j.gastro.2021.02.059","article-title":"The rs738409 G allele in PNPLA3 is associated with a reduced risk of COVID-19 mortality and hospitalization","volume":"160","author":"Innes","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.07.008_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.627914","article-title":"PNPLA3 and TLL-1 polymorphisms as potential predictors of disease severity in patients with COVID-19","volume":"9","author":"Grimaudo","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"10.1016\/j.jhep.2022.07.008_bib79","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jhep.2021.11.014","article-title":"Assessing causal relationships between COVID-19 and non-alcoholic fatty liver disease","volume":"76","author":"Liu","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2022.01.045","article-title":"Mendelian randomization analysis reveals no causal relationship between nonalcoholic fatty liver disease and severe COVID-19","author":"Li","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib81","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jhep.2022.07.008_bib82","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1136\/gutjnl-2020-322539","article-title":"Effect of IBD medications on COVID-19 outcomes: results from an international registry","volume":"70","author":"Ungaro","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.07.008_bib83","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S2468-1253(20)30271-5","article-title":"Outcomes following SARS-CoV-2 infection in liver transplant recipients: an international registry study","volume":"5","author":"Webb","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101025","article-title":"Impact of COVID-19 on liver transplant recipients-A systematic review and meta-analysis","volume":"38","author":"Kulkarni","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jhep.2022.07.008_bib85","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ueg2.12100","article-title":"Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: a patient-oriented online survey","volume":"9","author":"Zecher","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"10.1016\/j.jhep.2022.07.008_bib86","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jhep.2021.01.021","article-title":"SARS-CoV-2 infection in patients with autoimmune hepatitis","volume":"74","author":"Marjot","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib87","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1002\/hep.31797","article-title":"Outcome of COVID-19 in patients with autoimmune hepatitis: an international multicenter study","volume":"73","author":"Efe","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.008_bib88","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/liv.15121","article-title":"Effects of immunosuppressive drugs on COVID-19 severity in patients with autoimmune hepatitis","volume":"42","author":"Efe","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.07.008_bib89","article-title":"Primary biliary cholangitis and SARS-CoV-2 infection: incidence, susceptibility and outcomes","author":"Ampuero","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.07.008_bib90","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/hep.31890","article-title":"Current and past infections of HBV do not increase mortality in patients with COVID-19","volume":"74","author":"Yip","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.008_bib91","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258229","article-title":"Association between chronic hepatitis B infection and COVID-19 outcomes: a Korean nationwide cohort study","volume":"16","author":"Kang","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2022.07.008_bib92","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.jhep.2020.07.007","article-title":"SARS-CoV-2 in patients on antiviral HBV and HCV therapy in Spain","volume":"73","author":"Lens","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib93","doi-asserted-by":"crossref","first-page":"536","DOI":"10.7326\/M20-3689","article-title":"Incidence and severity of COVID-19 in HIV-positive persons receiving antiretroviral therapy : a cohort study","volume":"173","author":"Del Amo","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib94","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100993","article-title":"Effect of Tenofovir Disoproxil Fumarate and Emtricitabine on nasopharyngeal SARS-CoV-2 viral load burden amongst outpatients with COVID-19: a pilot, randomized, open-label phase 2 trial","volume":"38","author":"Parienti","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jhep.2022.07.008_bib95","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","article-title":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19","volume":"19","author":"Chien","year":"2020","journal-title":"J\u00a0Proteome Res"},{"key":"10.1016\/j.jhep.2022.07.008_bib96","doi-asserted-by":"crossref","first-page":"e01114","DOI":"10.1128\/mBio.01114-20","article-title":"Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets","volume":"11","author":"Park","year":"2020","journal-title":"MBio"},{"key":"10.1016\/j.jhep.2022.07.008_bib97","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1111\/liv.14804","article-title":"Mortality is not increased in SARS-CoV-2 infected persons with hepatitis C virus infection","volume":"41","author":"Butt","year":"2021","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2022.07.008_bib98","doi-asserted-by":"crossref","first-page":"8749","DOI":"10.12998\/wjcc.v9.i29.8749","article-title":"Chronic hepatitis-C infection in COVID-19 patients is associated with in-hospital mortality","volume":"9","author":"Ronderos","year":"2021","journal-title":"World J Clin Cases"},{"key":"10.1016\/j.jhep.2022.07.008_bib99","doi-asserted-by":"crossref","first-page":"597","DOI":"10.3390\/medicina57060597","article-title":"Liver impairment and hematological changes in patients with chronic hepatitis C and COVID-19: a retrospective study after one year of pandemic","volume":"57","author":"Cerbu","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.jhep.2022.07.008_bib100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jceh.2020.10.001","article-title":"Repurposing hepatitis C direct-acting antivirals against COVID-19","volume":"11","author":"Kumar","year":"2021","journal-title":"J\u00a0Clin Exp Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib101","first-page":"1","article-title":"Clinical outcomes of sofosbuvir-based antivirals in patients with COVID-19: a systematic review and meta-analysis of randomized trials","author":"Kow","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.jhep.2022.07.008_bib102","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2022.106545","article-title":"The effect of sofosbuvir-based treatment on the clinical outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials","author":"Hsu","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jhep.2022.07.008_bib103","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/S1470-2045(20)30442-3","article-title":"COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study","volume":"21","author":"Lee","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2022.07.008_bib104","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2020.07.040","article-title":"Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients","volume":"74","author":"Colmenero","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib105","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1111\/ajt.16247","article-title":"SARS-CoV-2 infection and early mortality of waitlisted and solid organ transplant recipients in England: a national cohort study","volume":"20","author":"Ravanan","year":"2020","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2022.07.008_bib106","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cmi.2021.09.036","article-title":"Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review","volume":"28","author":"Galmiche","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhep.2022.07.008_bib107","first-page":"4015","article-title":"COVID-19 in liver transplant recipients: a systematic review","volume":"10","author":"Becchetti","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib108","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jhep.2021.01.036","article-title":"Age and comorbidity are central to the risk of death from COVID-19 in liver transplant recipients","volume":"75","author":"Webb","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib109","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1111\/joim.13223","article-title":"Cyclosporine A plus low-dose steroid treatment in COVID-19 improves clinical outcomes in patients with moderate to severe disease: a pilot study","volume":"289","author":"G\u00e1lvez-Romero","year":"2021","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib110","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jhep.2018.06.010","article-title":"Impact of DAAs on liver transplantation: major effects on the evolution of indications and results. An ELITA study based on the ELTR registry","volume":"69","author":"Belli","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib111","article-title":"Methylprednisolone pulses plus tacrolimus in addition to standard of care vs. standard of care alone in patients with severe COVID-19. A randomized controlled trial","volume":"8","author":"Solanich","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jhep.2022.07.008_bib112","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41416-021-01685-3","article-title":"Cancer therapy with decreased SARS-CoV-2 infection rates in cancer patients","volume":"126","author":"Hayashi","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jhep.2022.07.008_bib113","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1053\/j.gastro.2020.11.045","article-title":"Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA\/ELTR multi-center European study","volume":"160","author":"Belli","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.07.008_bib114","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/jech-2020-215060","article-title":"Mental health and health behaviours before and during the initial phase of the COVID-19 lockdown: longitudinal analyses of the UK Household Longitudinal Study","volume":"75","author":"Niedzwiedz","year":"2021","journal-title":"J\u00a0Epidemiol Community Health"},{"key":"10.1016\/j.jhep.2022.07.008_bib115","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.22942","article-title":"Changes in adult alcohol use and consequences during the COVID-19 pandemic in the US","volume":"3","author":"Pollard","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhep.2022.07.008_bib116","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.7326\/M20-7271","article-title":"Retail alcohol and tobacco sales during COVID-19","volume":"174","author":"Lee","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib117","doi-asserted-by":"crossref","first-page":"E9189","DOI":"10.3390\/ijerph17249189","article-title":"Alcohol consumption during the COVID-19 pandemic: a cross-sectional survey of US adults","volume":"17","author":"Grossman","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jhep.2022.07.008_bib118","unstructured":"Rebalancing the \u2018COVID-19 effect\u2019 on alcohol sales - NielsenIQ n.d. https:\/\/nielseniq.com\/global\/en\/insights\/analysis\/2020\/rebalancing-the-covid-19-effect-on-alcohol-sales\/#:%7E:text=A%2520Nielsen%2520investigation%2520of%2520the,of%2520closed%2520bars%2520and%2520restaurants (accessed March 8, 2022)."},{"key":"10.1016\/j.jhep.2022.07.008_bib119","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S2468-1253(20)30251-X","article-title":"Effect of COVID-19 lockdown on alcohol consumption in patients with pre-existing alcohol use disorder","volume":"5","author":"Kim","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib120","unstructured":"Alcohol consumption and harm during the COVID-19 pandemic. GOVUK n.d. https:\/\/www.gov.uk\/government\/publications\/alcohol-consumption-and-harm-during-the-covid-19-pandemic (accessed March 8, 2022)."},{"key":"10.1016\/j.jhep.2022.07.008_bib121","article-title":"Impact of the COVID-19 pandemic on hospitalizations for alcoholic hepatitis or cirrhosis in Alberta, Canada","author":"Shaheen","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib122","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1002\/hep.32067","article-title":"Impact of COVID-19 pandemic on liver transplantation and alcohol-associated liver disease in the USA","volume":"74","author":"Cholankeril","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.008_bib123","article-title":"Effect of increased alcohol consumption during COVID-19 pandemic on alcohol-associated liver disease: a modeling study","author":"Julien","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.008_bib124","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1002\/hep4.1747","article-title":"Alcohol-associated liver disease before and after COVID-19-an overview and call for ongoing investigation","volume":"5","author":"Moon","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2022.07.008_bib125","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(13)62417-4","article-title":"Effects of minimum unit pricing for alcohol on different income and socioeconomic groups: a modelling study","volume":"383","author":"Holmes","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.07.008_bib126","doi-asserted-by":"crossref","first-page":"l5274","DOI":"10.1136\/bmj.l5274","article-title":"Immediate impact of minimum unit pricing on alcohol purchases in Scotland: controlled interrupted time series analysis for 2015-18","volume":"366","author":"O\u2019Donnell","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2022.07.008_bib127","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.07.008_bib128","doi-asserted-by":"crossref","first-page":"E2826","DOI":"10.3390\/nu12092826","article-title":"Eating habits and physical activity of the Spanish population during the COVID-19 pandemic period","volume":"12","author":"S\u00e1nchez-S\u00e1nchez","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.jhep.2022.07.008_bib129","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0252395","article-title":"Changes in physical activity levels, eating habits and psychological well-being during the Italian COVID-19 pandemic lockdown: impact of socio-demographic factors on the Florentine academic population","volume":"16","author":"Mascherini","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2022.07.008_bib130","doi-asserted-by":"crossref","first-page":"E2016","DOI":"10.3390\/nu12072016","article-title":"Changes in weight and nutritional habits in adults with obesity during the \u201clockdown\u201d period caused by the COVID-19 virus emergency","volume":"12","author":"Pellegrini","year":"2020","journal-title":"Nutrients"},{"key":"10.1016\/j.jhep.2022.07.008_bib131","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.15585\/mmwr.mm7037a3","article-title":"Longitudinal trends in body mass index before and during the COVID-19 pandemic among persons aged 2-19 years - United States, 2018-2020","volume":"70","author":"Lange","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jhep.2022.07.008_bib132","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/jamapediatrics.2021.5095","article-title":"Association of changes in obesity prevalence with the COVID-19 pandemic in youth in Massachusetts","volume":"176","author":"Wu","year":"2022","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jhep.2022.07.008_bib133","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S2213-8587(21)00116-9","article-title":"Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK","volume":"9","author":"Carr","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jhep.2022.07.008_bib134","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.2337\/dci21-0001","article-title":"Diabetes and COVID-19: population impact 18 months into the pandemic","volume":"44","author":"Gregg","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jhep.2022.07.008_bib135","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41575-020-0332-6","article-title":"Progress towards elimination goals for viral hepatitis","volume":"17","author":"Cox","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib136","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.amepre.2021.03.011","article-title":"Decreases in hepatitis C testing and treatment during the COVID-19 pandemic","volume":"61","author":"Kaufman","year":"2021","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib137","article-title":"Decrease in viral hepatitis diagnoses during the COVID-19 pandemic in the Netherlands","author":"Sonneveld","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib138","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jhep.2021.08.005","article-title":"Impact of the COVID-19 pandemic on hepatitis C diagnosis in Brazil: is the global hepatitis C elimination strategy at risk?","volume":"76","author":"do Carmo","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib139","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jhep.2020.12.018","article-title":"Impact of the COVID-19 pandemic on HCV elimination in Spain","volume":"74","author":"Buti","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib140","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jhep.2020.07.042","article-title":"Impact of COVID-19 on global HCV elimination efforts","volume":"74","author":"Blach","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib141","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jhep.2021.03.009","article-title":"Alliance for the Elimination of Viral Hepatitis in Spain. Let\u2019s leverage SARS-CoV2 vaccination to screen for hepatitis C in Spain, in Europe, around the world","volume":"75","author":"Crespo","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib142","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.jhep.2020.10.001","article-title":"SARS-CoV-2 massive testing: a window of opportunity to catch up with HCV elimination","volume":"74","author":"Crespo","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib143","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.jhep.2020.12.026","article-title":"Detecting HCV infection by means of mass population SARS-CoV-2 screening: a pilot experience in Northern Italy","volume":"75","author":"Giacomelli","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib144","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2020.04.005","article-title":"The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care","volume":"73","author":"Tapper","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib145","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jhep.2021.09.041","article-title":"Global impact of the first wave of COVID-19 on liver transplant centers: a multi-society survey (EASL-ESOT\/ELITA-ILTS)","volume":"76","author":"Russo","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib146","article-title":"Impact of COVID-19 on the management of hepatocellular carcinoma in a high-prevalence area","volume":"3","author":"Amaddeo","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2022.07.008_bib147","article-title":"Assessing the impact of COVID-19 on liver cancer management (CERO-19)","volume":"3","author":"Mu\u00f1oz-Mart\u00ednez","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jhep.2022.07.008_bib148","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMcp2009249","article-title":"Mild or moderate covid-19","volume":"383","author":"Gandhi","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2021.114800","article-title":"Remdesivir: Quo vadis?","volume":"193","author":"De Clercq","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jhep.2022.07.008_bib150","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib151","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 days in patients with severe Covid-19","volume":"383","author":"Goldman","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib152","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19 - interim WHO solidarity trial results","volume":"384","author":"Pan","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib153","article-title":"Remdesivir treatment in hospitalized patients with COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort","author":"Mozaffari","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2022.07.008_bib154","article-title":"Real-world effectiveness of remdesivir in adults hospitalized with Covid-19: a retrospective, multicenter comparative effectiveness study","author":"Garibaldi","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2022.07.008_bib155","article-title":"Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial","author":"Ader","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2022.07.008_bib156","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","author":"Gottlieb","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib157","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jhep.2022.07.008_bib158","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","author":"Hammond","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib159","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128629","article-title":"Main protease mutants of SARS-CoV-2 variants remain susceptible to nirmatrelvir","volume":"62","author":"Ullrich","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.jhep.2022.07.008_bib160","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41422-022-00618-w","article-title":"SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination","volume":"32","author":"Li","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.jhep.2022.07.008_bib161","first-page":"1170","article-title":"Electronic address: easloffice@easloffice.eu, Clinical Practice Guidelines Panel: Chair:, EASL Governing Board representative:, Panel members: EASL recommendations on treatment of hepatitis C: final update of the series","volume":"73","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib162","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41594-021-00651-0","article-title":"Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis","volume":"28","author":"Kabinger","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.jhep.2022.07.008_bib163","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients","volume":"386","author":"Jayk Bernal","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib164","article-title":"Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 model","author":"Rosenke","year":"2022","journal-title":"BioRxiv"},{"key":"10.1016\/j.jhep.2022.07.008_bib165","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105252","article-title":"Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern","volume":"198","author":"Vangeel","year":"2022","journal-title":"Antivir Res"},{"key":"10.1016\/j.jhep.2022.07.008_bib166","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1056\/NEJMoa2108163","article-title":"REGEN-COV antibody combination and outcomes in outpatients with Covid-19","volume":"385","author":"Weinreich","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib167","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus etesevimab in mild or moderate Covid-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib168","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib169","article-title":"SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19","author":"Kreuzberger","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2022.07.008_bib170","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.07.008_bib171","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2022.100470","article-title":"Monoclonal antibody therapy in kidney transplant recipients with delta and Omicron variants of SARS-CoV-2: a single-center case series","author":"Fernandes","year":"2022","journal-title":"Kidney Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib172","doi-asserted-by":"crossref","DOI":"10.1016\/j.kint.2022.04.003","article-title":"Early treatment with sotrovimab monoclonal antibody in kidney transplant recipients with Omicron infection","author":"Chavarot","year":"2022","journal-title":"Kidney Int"},{"key":"10.1016\/j.jhep.2022.07.008_bib173","doi-asserted-by":"crossref","DOI":"10.7326\/M22-0308","article-title":"Comparison of patients infected with delta versus omicron COVID-19 variants presenting to Paris emergency departments : a retrospective cohort study","author":"Bouzid","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib174","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-01792-5","article-title":"Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies","author":"Bruel","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib175","series-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages 2022","author":"Iketani","year":"2022"},{"key":"10.1016\/j.jhep.2022.07.008_bib176","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial","author":"Montgomery","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110812","article-title":"LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants","volume":"39","author":"Westendorf","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.jhep.2022.07.008_bib178","article-title":"Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany","volume":"8","author":"Jensen","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jhep.2022.07.008_bib179","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMc2120219","article-title":"Resistance mutations in SARS-CoV-2 delta variant after sotrovimab use","volume":"386","author":"Rockett","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib180","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1001\/jama.2021.2747","article-title":"Association of convalescent plasma treatment with clinical outcomes in patients with COVID-19: a systematic review and meta-analysis","volume":"325","author":"Janiaud","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2022.07.008_bib181","first-page":"CD013600","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review","volume":"5","author":"Piechotta","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2022.07.008_bib182","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with Covid-19","volume":"384","author":"Horby","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib183","article-title":"Systemic corticosteroids for the treatment of COVID-19","author":"Wagner","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2022.07.008_bib184","doi-asserted-by":"crossref","DOI":"10.1007\/s12072-022-10306-x","article-title":"Management of hepatitis B virus reactivation due to treatment of COVID-19","author":"Yip","year":"2022","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2022.07.008_bib185","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib186","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-2600(22)00006-6","article-title":"Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial","author":"Ely","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib188","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.jmii.2021.05.009","article-title":"Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: a retrospective analysis","volume":"54","author":"P\u00e9rez-Alba","year":"2021","journal-title":"J\u00a0Microbiol Immunol Infect"},{"key":"10.1016\/j.jhep.2022.07.008_bib189","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/ph14080738","article-title":"Janus kinase inhibitors and coronavirus disease (COVID)-19: rationale, clinical evidence and safety issues","volume":"14","author":"Gatti","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jhep.2022.07.008_bib190","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001095","article-title":"Evaluation of hepatitis B virus in clinical trials of baricitinib in rheumatoid arthritis","volume":"6","author":"Harigai","year":"2020","journal-title":"RMD Open"},{"key":"10.1016\/j.jhep.2022.07.008_bib191","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in patients hospitalized with Covid-19 pneumonia","volume":"385","author":"Guimar\u00e3es","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib192","first-page":"493","article-title":"Janus kinase inhibitors for the treatment of hospitalized patients with COVID-19","volume":"27","author":"Florescu","year":"2021","journal-title":"Curr Opin Crit Care"},{"key":"10.1016\/j.jhep.2022.07.008_bib193","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.07.008_bib194","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis","volume":"326","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2022.07.008_bib195","doi-asserted-by":"crossref","first-page":"R141","DOI":"10.1186\/ar3455","article-title":"Integrated safety in tocilizumab clinical trials","volume":"13","author":"Schiff","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.jhep.2022.07.008_bib196","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1136\/ard.2011.151092","article-title":"Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients","volume":"70","author":"Koike","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jhep.2022.07.008_bib197","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/1756-185X.13010","article-title":"Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation","volume":"20","author":"Chen","year":"2017","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.jhep.2022.07.008_bib198","doi-asserted-by":"crossref","first-page":"360","DOI":"10.3390\/idr14030040","article-title":"Sarilumab administration in COVID-19 patients: literature review and considerations","volume":"14","author":"Marino","year":"2022","journal-title":"Infect Dis Rep"},{"key":"10.1016\/j.jhep.2022.07.008_bib199","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-22-0162","article-title":"A\u00a0phase 1b\/2 study of sabizabulin, a novel oral cytoskeleton disruptor, in men with metastatic castration-resistant prostate cancer with progression on an androgen receptor targeting agent","author":"Markowski","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2022.07.008_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100981","article-title":"Nitazoxanide superiority to placebo to treat moderate COVID-19 - a Pilot prove of concept randomized double-blind clinical trial","volume":"37","author":"Blum","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jhep.2022.07.008_bib201","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03725-2020","article-title":"Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial","volume":"58","author":"Rocco","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jhep.2022.07.008_bib202","series-title":"Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization","author":"Rossignol","year":"2021"},{"key":"10.1016\/j.jhep.2022.07.008_bib203","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2115869","article-title":"Effect of early treatment with ivermectin among patients with Covid-19","author":"Reis","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib204","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1053\/j.gastro.2020.05.053","article-title":"Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study","volume":"159","author":"Freedberg","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.07.008_bib205","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.14309\/ajg.0000000000000832","article-title":"Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19","volume":"115","author":"Mather","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.07.008_bib206","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1053\/j.gastro.2020.10.011","article-title":"Famotidine use is not associated with 30-day mortality: a coarsened exact match study in 7158 hospitalized patients with coronavirus disease 2019 from a large healthcare system","volume":"160","author":"Yeramaneni","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.07.008_bib207","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1136\/gutjnl-2020-323668","article-title":"Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study","volume":"70","author":"Zhou","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.07.008_bib208","article-title":"Effect of famotidine on hospitalized patients with COVID-19: a systematic review and meta-analysis","volume":"16","author":"Chiu","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2022.07.008_bib209","doi-asserted-by":"crossref","first-page":"3929","DOI":"10.1007\/s10620-021-06872-z","article-title":"Does famotidine reduce the risk of progression to severe disease, death, and intubation for COVID-19 patients? A systemic review and meta-analysis","volume":"66","author":"Sun","year":"2021","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2022.07.008_bib210","doi-asserted-by":"crossref","DOI":"10.1136\/gutjnl-2022-326952","article-title":"Oral famotidine versus placebo in non-hospitalised patients with COVID-19: a randomised, double-blind, data-intense, phase 2 clinical trial","author":"Brennan","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2022.07.008_bib211","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s40265-021-01636-5","article-title":"Fluvoxamine for the early treatment of SARS-CoV-2 infection: a review of current evidence","volume":"81","author":"Facente","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.jhep.2022.07.008_bib212","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2214-109X(21)00448-4","article-title":"Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial","volume":"10","author":"Reis","year":"2022","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jhep.2022.07.008_bib213","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S2213-2600(21)00160-0","article-title":"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial","volume":"9","author":"Ramakrishnan","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib214","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(21)01744-X","article-title":"Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial","volume":"398","author":"Yu","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.07.008_bib215","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1001\/jamainternmed.2021.6759","article-title":"Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: a randomized clinical trial","volume":"182","author":"Clemency","year":"2022","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib216","article-title":"Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial","volume":"375","author":"Ezer","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2022.07.008_bib217","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0140-6736(21)00149-5","article-title":"Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.07.008_bib218","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0140-6736(20)31862-6","article-title":"Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial","volume":"396","author":"Furtado","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.07.008_bib219","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/S2213-2600(21)00435-5","article-title":"Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"9","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib220","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2213-2600(21)00222-8","article-title":"Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial","volume":"9","author":"Tardif","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib221","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.cytogfr.2022.01.001","article-title":"Current utilization of interferon alpha for the treatment of coronavirus disease 2019: a comprehensive review","volume":"63","author":"Lu","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jhep.2022.07.008_bib222","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S2213-2600(21)00384-2","article-title":"Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial","volume":"9","author":"Kalil","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib223","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s10517-021-05330-0","article-title":"Evaluation of the anti-viral activity of human recombinant interferon lambda-1 against SARS-CoV-2","volume":"172","author":"Madonov","year":"2021","journal-title":"Bull Exp Biol Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib224","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1038\/s41467-021-22177-1","article-title":"Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial","volume":"12","author":"Jagannathan","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jhep.2022.07.008_bib225","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2213-2600(20)30556-7","article-title":"Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial","volume":"9","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib226","article-title":"Vitamin D supplementation for the treatment of COVID-19: a living systematic review","author":"Stroehlein","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2022.07.008_bib227","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M20-2003","article-title":"Autopsy findings and venous thromboembolism in patients with COVID-19: a prospective cohort study","volume":"173","author":"Wichmann","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib228","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19","volume":"383","author":"Ackermann","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib229","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/S2213-2600(21)00455-0","article-title":"Prevention and management of thrombosis in hospitalised patients with COVID-19 pneumonia","volume":"10","author":"Vincent","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib230","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa2103417","article-title":"Therapeutic anticoagulation with heparin in critically ill patients with Covid-19","volume":"385","author":"Goligher","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib231","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/jama.2021.4152","volume":"325","author":"Sadeghipour","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2022.07.008_bib232","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19","volume":"385","author":"Lawler","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib233","doi-asserted-by":"crossref","first-page":"n2400","DOI":"10.1136\/bmj.n2400","article-title":"Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial","volume":"375","author":"Sholzberg","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2022.07.008_bib234","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1016\/S0140-6736(21)01203-4","article-title":"Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial","volume":"397","author":"Lopes","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.07.008_bib235","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1001\/jama.2021.17272","article-title":"Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic COVID-19: the ACTIV-4B randomized clinical trial","volume":"326","author":"Connors","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2022.07.008_bib236","article-title":"Randomized study of rivaroxaban vs. placebo on disease progression and symptoms resolution in high-risk adults with mild COVID-19","author":"Ananworanich","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2022.07.008_bib237","article-title":"Effect of aspirin on the prevention of pro-thrombotic states in hospitalized COVID-19 patients: systematic review","author":"Abdi","year":"2022","journal-title":"Cardiovasc Hematol Agents Med Chem"},{"key":"10.1016\/j.jhep.2022.07.008_bib238","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.3890","article-title":"Association of early aspirin use with in-hospital mortality in patients with moderate COVID-19","volume":"5","author":"Chow","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jhep.2022.07.008_bib239","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01825-0","article-title":"Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.07.008_bib240","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/ajg.2008.34","article-title":"Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study","volume":"104","author":"S\u00f8gaard","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2022.07.008_bib241","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1053\/j.gastro.2017.04.042","article-title":"Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis","volume":"153","author":"Loffredo","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2022.07.008_bib242","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3390\/vaccines9121422","article-title":"Humoral immune response following SARS-CoV-2 vaccination in liver transplant recipients","volume":"9","author":"Timmermann","year":"2021","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jhep.2022.07.008_bib243","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.02.015","article-title":"Past COVID-19 and immunosuppressive regimens affect the long-term response to anti-SARS-CoV-2 vaccination in liver transplant recipients","author":"Toniutto","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib244","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157836","article-title":"Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients","author":"Schrezenmeier","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.jhep.2022.07.008_bib245","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1099\/vir.0.034983-0","article-title":"Cyclosporin A inhibits the replication of diverse coronaviruses","volume":"92","author":"de Wilde","year":"2011","journal-title":"J\u00a0Gen Virol"},{"key":"10.1016\/j.jhep.2022.07.008_bib246","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.3390\/ph14121256","article-title":"Antirheumatic drugs against COVID-19 from the perspective of rheumatologists","volume":"14","author":"Kawazoe","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jhep.2022.07.008_bib247","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.16958","article-title":"mTOR inhibitors improve both humoral and cellular response to SARS-CoV-2 messenger RNA BNT16b2 vaccine in kidney transplant recipients","author":"Netti","year":"2022","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2022.07.008_bib248","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1158\/2159-8290.CD-20-0596","article-title":"Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers","volume":"10","author":"Luo","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2022.07.008_bib249","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/oncolo\/oyab083","article-title":"Impact of immune checkpoint inhibitors on COVID-19 severity in patients with cancer","volume":"27","author":"Tan","year":"2022","journal-title":"Oncologist"},{"key":"10.1016\/j.jhep.2022.07.008_bib250","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/QCO.0000000000000739","article-title":"Coronavirus disease 2019 vaccination in transplant recipients","volume":"34","author":"Eberhardt","year":"2021","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jhep.2022.07.008_bib251","first-page":"71","article-title":"Effectiveness of COVID-19 mRNA vaccination in preventing COVID-19\u2013associated hospitalization among adults with previous SARS-CoV-2 infection \u2014 United States, June 2021\u2013February 2022","author":"Plumb","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jhep.2022.07.008_bib252","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 vaccine effectiveness against the Omicron (B.1.1.529) variant","author":"Andrews","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib253","article-title":"Safety and immunogenicity of SARS-CoV-2 vaccines in patients with chronic liver diseases (CHESS-NMCID 2101): a multicenter study","author":"Ai","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib254","doi-asserted-by":"crossref","DOI":"10.1002\/hep.32337","article-title":"Postvaccination COVID-19 infection is associated with reduced mortality in patients with cirrhosis","author":"John","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.008_bib255","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13705","article-title":"Clinical effectiveness of COVID-19 vaccination in solid organ transplant recipients","volume":"23","author":"Aslam","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jhep.2022.07.008_bib256","article-title":"SARS-CoV-2 infections among patients with liver disease and liver transplantation who received COVID-19 vaccination","author":"Moon","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jhep.2022.07.008_bib257","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.02.013","article-title":"Autoimmune hepatitis and COVID-19: No increased risk for AIH after vaccination but reduced care","author":"R\u00fcther","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib258","doi-asserted-by":"crossref","DOI":"10.1002\/hep.32572","article-title":"Liver injury after SARS-CoV-2 vaccination: features of immune-mediated hepatitis, role of corticosteroid therapy and outcome","author":"Efe","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.008_bib259","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1002\/hep.32409","article-title":"Letter to the editor: liver transplantation following severe acute respiratory syndrome-coronavirus-2 vaccination-induced liver failure","volume":"75","author":"Efe","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.008_bib260","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2022.03.040","article-title":"SARS-CoV-2 vaccination can elicit a CD8 T-cell dominant hepatitis","author":"Boettler","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib261","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1056\/NEJMra1816149","article-title":"Drug-induced liver injury - types and phenotypes","volume":"381","author":"Hoofnagle","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib262","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jhep.2021.04.003","article-title":"Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: causality or casualty?","volume":"75","author":"Bril","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib263","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102710","article-title":"Autoimmune hepatitis triggered by SARS-CoV-2 vaccination","volume":"123","author":"Vuille-Lessard \u00c9","year":"2021","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jhep.2022.07.008_bib264","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.jhep.2021.05.038","article-title":"Autoimmune hepatitis following SARS-CoV-2 vaccine: may not be a casuality","volume":"75","author":"Rocco","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib265","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jhep.2021.07.005","article-title":"An unusual case of acute cholestatic hepatitis after m-RNABNT162b2 (Comirnaty) SARS-CoV-2 vaccine: coincidence, autoimmunity or drug-related liver injury","volume":"75","author":"Lodato","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib266","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102706","article-title":"Acute autoimmune-like hepatitis with atypical anti-mitochondrial antibody after mRNA COVID-19 vaccination: a novel clinical entity?","volume":"123","author":"Ghielmetti","year":"2021","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jhep.2022.07.008_bib267","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jhep.2021.09.031","article-title":"Immune-mediated hepatitis with the Moderna vaccine, no longer a coincidence but confirmed","volume":"76","author":"Zin Tun","year":"2022","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib268","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.jhep.2021.06.004","article-title":"Another case of autoimmune hepatitis after SARS-CoV-2 vaccination - still casualty?","volume":"75","author":"Londo\u00f1o","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib269","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jhep.2021.06.009","article-title":"Autoimmune hepatitis following COVID-19 vaccination: true causality or mere association?","volume":"75","author":"Tan","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib270","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jhep.2021.06.014","article-title":"Autoimmune hepatitis developing after the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccine","volume":"75","author":"Clayton-Chubb","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib271","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.jhep.2021.06.044","article-title":"The mRNA COVID-19 vaccine - a rare trigger of autoimmune hepatitis?","volume":"75","author":"McShane","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib272","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/hep.32269","article-title":"Letter to the editor: exacerbation of autoimmune hepatitis after COVID-19 vaccination","volume":"75","author":"Cao","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.008_bib273","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102741","article-title":"Autoimmune hepatitis after COVID-19 vaccine - more than a coincidence","volume":"125","author":"Garrido","year":"2021","journal-title":"J\u00a0Autoimmun"},{"key":"10.1016\/j.jhep.2022.07.008_bib274","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/hep.32156","article-title":"Letter to the editor: autoimmune hepatitis after COVID-19 vaccination: a rare adverse effect?","volume":"75","author":"Palla","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2022.07.008_bib275","doi-asserted-by":"crossref","first-page":"e600","DOI":"10.7861\/clinmed.2021-0488","article-title":"VITT, COVID-19 and the Expert Haematology Panel: the story of how the UK responded to emerging cases of vaccine-induced immune thrombocytopenia and thrombosis during the vaccination programme","volume":"21","author":"Chevassut","year":"2021","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.jhep.2022.07.008_bib276","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1056\/NEJMe2106315","article-title":"SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia","volume":"384","author":"Cines","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib277","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijid.2021.12.352","article-title":"Clinical significance of hepatosplenic thrombosis in vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCoV-19 vaccination","volume":"116","author":"Hwang","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jhep.2022.07.008_bib278","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1001\/jamacardio.2021.3444","article-title":"Clinical characteristics and pharmacological management of COVID-19 vaccine-induced immune thrombotic thrombocytopenia with cerebral venous sinus thrombosis: a review","volume":"6","author":"Rizk","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jhep.2022.07.008_bib279","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2021013231","article-title":"Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia","volume":"138","author":"Greinacher","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jhep.2022.07.008_bib280","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S2468-1253(21)00197-7","article-title":"Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccination","volume":"6","author":"\u00d6cal","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib281","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3390\/v14020207","article-title":"Antibody responses after SARS-CoV-2 vaccination in patients with liver diseases","volume":"14","author":"Bakasis","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.jhep.2022.07.008_bib282","doi-asserted-by":"crossref","first-page":"377","DOI":"10.3390\/vaccines10030377","article-title":"Patients with liver cirrhosis show high immunogenicity upon COVID-19 vaccination but develop premature deterioration of antibody titers","volume":"10","author":"Willuweit","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jhep.2022.07.008_bib283","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jhep.2021.08.008","article-title":"Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases","volume":"75","author":"Thuluvath","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib284","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/ajt.16775","article-title":"Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients","volume":"22","author":"Del Bello","year":"2022","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2022.07.008_bib285","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.16950","article-title":"Anti-SARS-CoV-2 spike protein and neutralizing antibodies at 1 and 3 months after three doses of SARS-CoV-2 vaccine in a large cohort of solid organ transplant patients","author":"Kamar","year":"2022","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2022.07.008_bib286","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1056\/NEJMc2111462","article-title":"Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients","volume":"385","author":"Hall","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib287","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.kint.2021.09.014","article-title":"Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients","volume":"100","author":"Bertrand","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.jhep.2022.07.008_bib288","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.healun.2021.08.010","article-title":"Third dose of the BNT162b2 vaccine in heart transplant recipients: immunogenicity and clinical experience","volume":"41","author":"Peled","year":"2022","journal-title":"J\u00a0Heart Lung Transpl"},{"key":"10.1016\/j.jhep.2022.07.008_bib289","article-title":"mRNA vaccine effectiveness against COVID-19 hospitalization among solid organ transplant recipients","author":"Kwon","year":"2022","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.jhep.2022.07.008_bib290","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.01.015","article-title":"SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron","author":"Tarke","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2022.07.008_bib291","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-022-04460-3","article-title":"T\u00a0cell responses to SARS-CoV-2 spike cross-recognize Omicron","author":"Keeton","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2022.07.008_bib292","doi-asserted-by":"crossref","DOI":"10.1038\/s41564-022-01106-y","article-title":"SARS-CoV-2-specific T-cell epitope repertoire in convalescent and mRNA-vaccinated individuals","author":"Lang-Meli","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jhep.2022.07.008_bib293","article-title":"Protection against the omicron variant from previous SARS-CoV-2 infection","author":"Altarawneh","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib294","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abn8590","article-title":"SARS-CoV-2 Omicron-neutralizing memory B-cells are elicited by two doses of BNT162b2 mRNA vaccine","author":"Kotaki","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jhep.2022.07.008_bib295","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jamaneurol.2022.0245","article-title":"Omicron-specific cytotoxic T-cell responses after a third dose of mRNA COVID-19 vaccine among patients with multiple sclerosis treated with ocrelizumab","volume":"79","author":"Madelon","year":"2022","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jhep.2022.07.008_bib296","article-title":"Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2022.07.008_bib297","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abo2202","article-title":"Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients","author":"GeurtsvanKessel","year":"2022","journal-title":"Sci Immunol"},{"key":"10.1016\/j.jhep.2022.07.008_bib298","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2201570","article-title":"Protection by a fourth dose of BNT162b2 against Omicron in Israel","author":"Bar-On","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib299","doi-asserted-by":"crossref","first-page":"217","DOI":"10.15585\/mmwr.mm7106e2","volume":"71","author":"Modes","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jhep.2022.07.008_bib300","doi-asserted-by":"crossref","DOI":"10.7326\/L21-0598","article-title":"Antibody response to a fourth messenger RNA COVID-19 vaccine dose in kidney transplant recipients: a case series","author":"Caillard","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib301","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination","volume":"27","author":"Barros-Martins","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib302","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","author":"Atmar","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib303","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.07.008_bib304","article-title":"Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: a nationwide cohort study","volume":"11","author":"Nordstr\u00f6m","year":"2021","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jhep.2022.07.008_bib305","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"Costa Clemens","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.07.008_bib306","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41591-021-01325-6","article-title":"Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2","volume":"27","author":"Ebinger","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib307","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1056\/NEJMc2101667","article-title":"Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine","volume":"384","author":"Krammer","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib308","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-022-01715-4","article-title":"Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern","author":"Wratil","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib309","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1097\/TP.0000000000003900","article-title":"SARS-CoV-2 messenger RNA vaccine immunogenicity in solid organ transplant recipients with prior COVID-19","volume":"105","author":"Boyarsky","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.jhep.2022.07.008_bib310","series-title":"Prior SARS-CoV2 infection in vaccinated solid organ transplant recipients induces potent neutralization responses against variants, including Omicron","author":"Choudhary","year":"2022"},{"key":"10.1016\/j.jhep.2022.07.008_bib311","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S1473-3099(21)00648-4","article-title":"Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study","volume":"22","author":"Singanayagam","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jhep.2022.07.008_bib312","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1056\/NEJMoa2116597","article-title":"Effect of covid-19 vaccination on transmission of alpha and delta variants","volume":"386","author":"Eyre","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib313","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jhep.2022.07.008_bib314","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S0140-6736(21)02183-8","article-title":"Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study","volume":"398","author":"Tartof","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2022.07.008_bib315","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib316","doi-asserted-by":"crossref","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","volume":"374","author":"Goel","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.jhep.2022.07.008_bib317","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.17020","article-title":"Neutralization against Omicron variant in transplant recipients after three doses of mRNA vaccine","author":"Kumar","year":"2022","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2022.07.008_bib318","article-title":"Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals","volume":"2","author":"Tarke","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib319","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1111\/ajt.16768","article-title":"Cellular and humoral immune response after mRNA-1273 SARS-CoV-2 vaccine in liver and heart transplant recipients","volume":"21","author":"Herrera","year":"2021","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2022.07.008_bib320","doi-asserted-by":"crossref","first-page":"3980","DOI":"10.1111\/ajt.16766","article-title":"Humoral and cellular immune response and safety of two-dose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients","volume":"21","author":"Hall","year":"2021","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2022.07.008_bib321","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2022.105098","article-title":"Accuracy and real life performance of a novel interferon-\u03b3 release assay for the detection of SARS-CoV2 specific T cell response","volume":"148","author":"Huzly","year":"2022","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.jhep.2022.07.008_bib322","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac045","article-title":"Long term accuracy of SARS-CoV-2 interferon-\u03b3 release assay and its application in household investigation","author":"Murugesan","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2022.07.008_bib323","article-title":"Clinical performance of a standardized SARS-CoV-2 interferon-\u03b3 release assay for simple detection of T-cell responses after infection or vaccination","author":"Fern\u00e1ndez-Gonz\u00e1lez","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2022.07.008_bib324","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/ajt.16878","article-title":"Ethical review of COVID-19 vaccination requirements for transplant center staff and patients","volume":"22","author":"Kates","year":"2022","journal-title":"Am J Transpl"},{"key":"10.1016\/j.jhep.2022.07.008_bib325","doi-asserted-by":"crossref","first-page":"93","DOI":"10.14745\/ccdr.v46i04a06","article-title":"Motivational interviewing: a powerful tool to address vaccine hesitancy","volume":"46","author":"Gagneur","year":"2020","journal-title":"Can Commun Dis Rep"},{"key":"10.1016\/j.jhep.2022.07.008_bib326","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jhep.2021.04.020","article-title":"Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients","volume":"75","author":"Rabinowich","year":"2021","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2022.07.008_bib327","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2022.07.008_bib328","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.7326\/M21-1341","article-title":"Safety and immunogenicity of anti-SARS-CoV-2 messenger RNA vaccines in recipients of solid organ transplants","volume":"174","author":"Marion","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib329","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14600","article-title":"Early humoral immune response to two doses of severe acute respiratory syndrome coronavirus 2 vaccine in a diverse group of solid organ transplant candidates and recipients","author":"Huang","year":"2022","journal-title":"Clin Transpl"},{"key":"10.1016\/j.jhep.2022.07.008_bib330","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV antibody combination to prevent Covid-19","volume":"385","author":"O\u2019Brien","year":"2021","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib331","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for prevention of Covid-19","author":"Levin","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2022.07.008_bib332","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1001\/jama.2021.24931","article-title":"Tixagevimab and cilgavimab (Evusheld) for pre-exposure prophylaxis of COVID-19","volume":"327","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2022.07.008_bib333","article-title":"Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2","author":"Takashita","year":"2022","journal-title":"N\u00a0Engl J Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822029427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827822029427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:48:42Z","timestamp":1759175322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827822029427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":333,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0168827822029427"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2022.07.008","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of COVID-19 on the liver and on the care of patients with chronic liver disease, hepatobiliary cancer, and liver transplantation: An updated EASL position paper","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2022.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}